Authors

Reshma Mahtani, Miami Cancer InstituteFollow

PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer

Publication Date

6-10-2024

Content Type

Article

PubMed ID:

38513188

Additional Authors:

Additional authors and institutional affiliations

Citation

Mayer, E. L., Ren, Y., Wagle, N., Mahtani, R., Ma, C., DeMichele, A., Cristofanilli, M., Meisel, J., Miller, K. D., Abdou, Y., Riley, E. C., Qamar, R., Sharma, P., Reid, S., Sinclair, N., Faggen, M., Block, C. C., Ko, N., Partridge, A. H., Chen, W. Y., … Tolaney, S. M. (2024). PACE: A Randomized Phase II Study of Fulvestrant, Palbociclib, and Avelumab After Progression on Cyclin-Dependent Kinase 4/6 Inhibitor and Aromatase Inhibitor for Hormone Receptor-Positive/Human Epidermal Growth Factor Receptor-Negative Metastatic Breast Cancer. Journal of clinical oncology : official journal of the American Society of Clinical Oncology, 42(17), 2050–2060. https://doi.org/10.1200/JCO.23.01940